JP5954889B2 - ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤 - Google Patents

２−オキソ−１−ピロリジン誘導体を含む持続放出製剤 Download PDF

Info

Publication number
JP5954889B2
JP5954889B2 JP2011543762A JP2011543762A JP5954889B2 JP 5954889 B2 JP5954889 B2 JP 5954889B2 JP 2011543762 A JP2011543762 A JP 2011543762A JP 2011543762 A JP2011543762 A JP 2011543762A JP 5954889 B2 JP5954889 B2 JP 5954889B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
weight
layer
controlled release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011543762A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012509356A (ja
Inventor
ファナラ、ドメニコ
エークマン、フレデリック
ベルウェアー、モニク
Original Assignee
ユセベ ファルマ ソシエテ アノニム
ユセベ ファルマ ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユセベ ファルマ ソシエテ アノニム, ユセベ ファルマ ソシエテ アノニム filed Critical ユセベ ファルマ ソシエテ アノニム
Publication of JP2012509356A publication Critical patent/JP2012509356A/ja
Application granted granted Critical
Publication of JP5954889B2 publication Critical patent/JP5954889B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2011543762A 2008-11-18 2009-11-17 ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤 Active JP5954889B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08105817.4 2008-11-18
EP08105817 2008-11-18
EP09100311.1 2009-06-02
EP09100311 2009-06-02
PCT/EP2009/065270 WO2010057869A1 (en) 2008-11-18 2009-11-17 Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015071166A Division JP2015143256A (ja) 2008-11-18 2015-03-31 ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤

Publications (2)

Publication Number Publication Date
JP2012509356A JP2012509356A (ja) 2012-04-19
JP5954889B2 true JP5954889B2 (ja) 2016-07-20

Family

ID=41395028

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011543762A Active JP5954889B2 (ja) 2008-11-18 2009-11-17 ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
JP2015071166A Pending JP2015143256A (ja) 2008-11-18 2015-03-31 ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015071166A Pending JP2015143256A (ja) 2008-11-18 2015-03-31 ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤

Country Status (18)

Country Link
US (1) US8460712B2 (enExample)
EP (1) EP2358361B1 (enExample)
JP (2) JP5954889B2 (enExample)
KR (2) KR20110089184A (enExample)
CN (2) CN104083341A (enExample)
AU (1) AU2009317279B2 (enExample)
BR (1) BRPI0921301A2 (enExample)
CA (1) CA2741038C (enExample)
DK (1) DK2358361T3 (enExample)
EA (1) EA019583B1 (enExample)
ES (1) ES2602606T3 (enExample)
HK (1) HK1198288A1 (enExample)
HU (1) HUE030963T2 (enExample)
IL (1) IL212271A (enExample)
MX (1) MX356281B (enExample)
PL (1) PL2358361T3 (enExample)
PT (1) PT2358361T (enExample)
WO (1) WO2010057869A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2741041C (en) * 2008-11-18 2015-01-13 Ucb Pharma S.A. Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative
AU2016381366A1 (en) 2015-12-30 2018-06-28 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
WO2017195144A1 (en) * 2016-05-12 2017-11-16 Jubilant Generics Limited Pharmaceutical compositions comprising brivaracetam
WO2022238401A1 (en) * 2021-05-11 2022-11-17 Advicenne Prolonged-release pharmaceutical composition for oral administration of sultiame
CN115721624A (zh) * 2021-08-25 2023-03-03 北京海美源医药科技有限公司 一种布立西坦药物组合物及其制备方法和其应用
WO2025128057A1 (en) * 2023-12-13 2025-06-19 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A sachet formulation comprising brivaracetam

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses
JP5739080B2 (ja) 2005-01-27 2015-06-24 アレムビック・リミテッドＡｌｅｍｂｉｃ Ｌｉｍｉｔｅｄ レベチラセタムの徐放性製剤
US20070298098A1 (en) * 2005-02-16 2007-12-27 Elan Pharma International Limited Controlled Release Compositions Comprising Levetiracetam
WO2006088864A1 (en) * 2005-02-16 2006-08-24 Elan Pharma International Limited Controlled release compositions comprising levetiracetam
EP1909770B1 (en) 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
EP1863453A2 (en) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
FR2897267A1 (fr) * 2006-02-16 2007-08-17 Flamel Technologies Sa Formes pharmaceutiques multimicroparticulaires pour administration per os
EP2041084B1 (en) * 2006-06-08 2013-11-06 UCB Pharma, S.A. Co-crystals of pyrrolidinones
CA2661683C (en) * 2006-08-31 2015-11-24 Eurand, Inc Drug delivery systems comprising solid solutions of weakly basic drugs
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
PL2187875T3 (pl) * 2007-09-21 2013-01-31 Evonik Roehm Gmbh Kompozycja farmaceutyczna o zależnym od pH kontrolowanym uwalnianiu dla nieopioidów z odpornością przed wpływem etanolu
ES2474945T3 (es) * 2008-03-03 2014-07-10 Ucb Pharma, S.A. Soluciones farmacéuticas, procedimiento de preparación y usos terapéuticos

Also Published As

Publication number Publication date
CN104083341A (zh) 2014-10-08
HK1198288A1 (en) 2015-03-27
EA201100753A1 (ru) 2012-01-30
DK2358361T3 (en) 2016-12-12
BRPI0921301A2 (pt) 2015-12-29
KR20110089184A (ko) 2011-08-04
US8460712B2 (en) 2013-06-11
CA2741038A1 (en) 2010-05-27
JP2015143256A (ja) 2015-08-06
MX356281B (es) 2018-05-22
KR20170007528A (ko) 2017-01-18
AU2009317279A1 (en) 2010-05-27
EA019583B1 (ru) 2014-04-30
EP2358361B1 (en) 2016-09-14
WO2010057869A1 (en) 2010-05-27
CA2741038C (en) 2015-01-13
ES2602606T3 (es) 2017-02-21
IL212271A (en) 2016-10-31
JP2012509356A (ja) 2012-04-19
IL212271A0 (en) 2011-06-30
AU2009317279B2 (en) 2013-10-24
HUE030963T2 (en) 2017-06-28
EP2358361A1 (en) 2011-08-24
US20110274762A1 (en) 2011-11-10
MX2011004572A (es) 2011-06-17
KR101788804B1 (ko) 2017-10-20
CN102215828A (zh) 2011-10-12
PL2358361T3 (pl) 2017-02-28
PT2358361T (pt) 2016-11-18

Similar Documents

Publication Publication Date Title
JP5954890B2 (ja) ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
US8563036B2 (en) Pharmaceutical compositions comprising Brivaracetam
AU2010209790B2 (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives
JP2015143256A (ja) ２−オキソ−１−ピロリジン誘導体を含む持続放出製剤
HK1159502A (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivate
HK1159503B (en) Prolonged release formulations comprising an 2-oxo-1-pyrrolidine derivative

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120531

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140717

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150331

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20150407

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20150501

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160613

R150 Certificate of patent or registration of utility model

Ref document number: 5954889

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250